Two senior partners with more than 50 years of combined pharma leadership, most of it in vaccines, run your commercial and medical presence in both markets, without the cost and lead time of building a local organisation.
years of combined leadership, most of it in vaccines
weeks from agreement to an active mandate
Every mandate is delivered by the two partners personally.
Booked as an ongoing mandate or as a clearly defined project.
Market and competitive analysis, pricing and reimbursement strategy, business cases and forecasts that are ready for a decision.
Medical education, expert and advisory programmes, stakeholder management and congress work, promotional or non-promotional.
Evidence and dialogue for recommendation bodies such as STIKO, from the first dossier to an expanded recommendation.
Wholesale and pharmacy channel, ordering and returns agreements, so that a product can actually be ordered.
We run the market for you. imunaris covers sales, medical affairs and marketing, our partner network covers marketing authorisation, quality assurance, logistics and order processing.
Product selection, licence negotiation, regulatory dossier and exclusive distribution for Switzerland.
Selected results from our careers in the vaccine industry.
Global launch of a Japanese encephalitis vaccine through the travel clinic channel, and global marketing lead for a travel vaccine portfolio worth USD 200 m.
Swiss launch of the adjuvanted influenza vaccine Fluad, and years of medical affairs and market access work on seasonal and pandemic influenza.
H1N1 pandemic vaccine supply agreement with the Swiss federal health authority, and negotiations in European pandemic tenders that closed contracts in several countries.
Medical and market access work with STIKO, ECDC, JCVI, ACIP and WHO that contributed to an expanded paediatric vaccine recommendation.
Global pricing strategy for a dengue vaccine across more than 20 launch countries, and a long-term PAHO supply agreement.
Rotavirus, MMRV and TBE vaccine launches in Switzerland, with the TBE market share raised from 20% to over 50%.
Client names stay with us. Status autumn 2026.
Non-promotional reference materials and education for the Swiss pharmacy channel on RSV, shingles, influenza and further vaccines.
Vaccines · SwitzerlandMarket entry in Germany for an EU-approved vaccine, from pricing and ordering route to market launch.
Vaccines · GermanyWe use AI where it makes processes leaner and teams more effective, and we help pharma companies do the same: from the first assessment to a validated solution in daily use.
Where does AI pay off in your company, and what has to be in place first? We assess processes, data and systems and show the quickest path to real value.
From use case to daily operation: selection, set-up, validation and training of your teams, compliant with GxP and data protection, with local models on your own hardware where needed.
Manual and paper-based routines become lean digital workflows, so your experts spend their time where expertise counts.
AI makes our own processes faster and leaner every day. We recommend what we run ourselves.
More than 50 years of combined experience with Swiss and German pharma rules. We know where AI helps and where the rules draw the line.
Our own AI-supported quality management system follows the GAMP 5 approach, with change control and documented model changes, and keeps the coming EU GMP Annex 22 on AI in view. In pilot with a Swiss wholesaler.
The Responsible Person (FvP) is personally accountable for every supplier, every release and every regulatory change under Swiss law. Yet much of this work still runs on spreadsheets, paper checklists and e-mail. We are building an electronic quality management system for Swiss pharmaceutical wholesale that brings supplier qualification, goods receipt, document control and regulatory monitoring together, built on GDP and GAMP 5 principles, with a local AI model so sensitive data stays in-house. The FvP still decides every step.
Licences in the official registers are checked routinely instead of by hand, partner by partner.
Checks, deviations and releases in one place, traceable at any time.
New rules surface automatically, already mapped to the SOPs they affect.
Versioned, signed documents and a complete chain of evidence, without a last-minute search.
Founded in September 2025, when a vaccine close to our hearts lost its Swiss distributor and the manufacturer found no replacement because the market seemed too small. imunaris exists for exactly these products.

More than 20 years of commercial leadership in vaccines at GSK, Novartis and Takeda. Country Head Vaccines and Diagnostics Switzerland at Novartis, global marketing lead for a travel vaccine portfolio, and global pricing and market access for a dengue vaccine.
MBA, University of Rochester (Simon Business School). Background in chemistry and computer science.
LinkedIn
About 30 years in pharma, about 20 of them in medical affairs for vaccines and infectious disease. 8 years at Novartis Vaccines in Germany, Interim Head of Medical Affairs Europe at Seqirus, and medical launch lead for a dengue vaccine in non-endemic markets.
Dr. rer. physiol. in tumour immunology, University of Tübingen. MHBA, University of Erlangen-Nürnberg.
LinkedInimunaris is a member of the Swiss Biotech Association, the industry association of the Swiss biotech sector.